Home / Companies / News / Avra Laboratories gets regulatory approval for Covid-19 drug Favipiravir

Avra Laboratories gets regulatory approval for Covid-19 drug Favipiravir

The company said the drug is cheaper than alternatives and would be supplied to Cipla for the launch of Ciplenza, the generic version of Favipiravir

Favipiravir, Umifenovir, atniviral, drugs, pharma, coronavirus, covid-19, sars, cov-2

Premium

The company has got regulatory approval to manufacture and market Favipiravir API

1 min read Last Updated : Jul 27 2020 | 1:53 PM IST

Hyderabad-based Avra Laboratories Pvt Ltd said on Monday it has got regulatory approval to manufacture and market Favipiravir API, a drug for treating Covid-19 patients.

The company said the drug is cheaper than alternatives and would be supplied to Cipla for the launch of Ciplenza, the generic version of Favipiravir.

“I am very pleased to be working with Cipla and Dr Yusuf Hamied again with whom I share a five-decade long association and friendship, during which time we collaborated on several projects to produce lifesaving drugs including anti-cancer, anti-HIV/AIDS and several other generic products,” said Dr. A V Rama Rao, chairman of

What you get on BS Premium?

Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
Pick your 5 favourite companies, get a daily email with all news updates on them.
Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
Preferential invites to Business Standard events.
Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.

VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in